CNTA 240719 7.50C (CNTA240719C7500) Stock Options, News & Quotes

US OptionsDetailed Quotes

CNTA240719C7500

Watchlist

4.40
0.000.00%

15min DelayClose Mar 19 15:55 ET

0.00High0.00Low

Intraday

5D
Daily

News

Centessa Pharmaceuticals Price Target Announced at $14.00/Share by Oppenheimer
Centessa Pharmaceuticals Price Target Announced at $14.00/Share by
Dow JonesJul 18 09:01 ET
Centessa Pharmaceuticals Initiated at Outperform by Oppenheimer
Centessa Pharmaceuticals Initiated at Outperform by
Dow JonesJul 18 09:01 ET
Oppenheimer Initiates Centessa Pharmaceuticals(CNTA.US) With Buy Rating, Announces Target Price $14
Oppenheimer analyst Francois Brisebois initiates coverage on $Centessa Pharmaceuticals(CNTA.US)$ with a buy rating, and sets the target price at $14.According to TipRanks data, the analyst has a
Moomoo NewsJul 18 08:34 ET · Ratings
Express News | Centessa Pharmaceuticals PLC : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $14
ReutersJul 18 07:46 ET
Oppenheimer Initiates Centessa Pharmaceuticals at Outperform Rating With $14 Price Target
Centessa Pharmaceuticals (CNTA) has an average buy rating and a price target range of $11 to $20, according to analysts polled by Capital IQ.
MT NewswiresJul 18 07:21 ET
Centessa Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Centessa Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Dow JonesJun 21 10:25 ET

Comments

Trytosaveabit

Apr 23 15:37

Update

$Centessa Pharmaceuticals(CNTA.US)$ Press Release: Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Dow Jones· 15 mins ago
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for p...

Trytosaveabit

Apr 22 06:10

Update

$Centessa Pharmaceuticals(CNTA.US)$ The FDA Has Cleared Centessa Pharmaceuticals' Investigational New Drug Application To Initiate A Phase 1 First-in-human, Clinical Trial Of ORX750 For Narcolepsy

Meltyy

Apr 2 22:13

Gear up for AACR24!

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...

JESSE JAMES8832

Feb 10 10:15

buy

$Centessa Pharmaceuticals(CNTA.US)$

Trytosaveabit

Dec 10, 2023 12:04

Update

$Centessa Pharmaceuticals(CNTA.US)$ BOSTON and LONDON, Dec. 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced new data from an additional 52-weeks of continuous treatment from the third year (Part 5) of the ongoing Phase 2a study of SerpinPC for the treatment of hemophilia. The data were shared in a poster presentation at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10, 2023. SerpinPC is an investigational subcutaneously...